The 99th Annual Meeting of the Japanese Pharmacological Society

Chair:Takeo Yoshikawa(Hokkaido University Graduate School of Medicine)

While new modalities such as antibody-drug conjugates (ADCs) and chimeric antigen receptor T cells (CAR-T) are being developed in cancer antibody therapeutics, toxicity to normal tissues remains a persistent concern. To address this, we have developed CasMab technology for creating cancer-specific antibodies against membrane proteins, as well as the Cell-Based Immunization and Screening (CBIS) method, which enables the rapid generation of antibodies even against challenging targets. We are currently developing CasMabs for various membrane proteins through AMED projects and collaborative research with pharmaceutical companies. The key elements in generating CasMabs are target selection, antigen preparation, and screening methods, which do not necessarily require entirely new technologies. In this presentation, I will introduce our latest findings, focusing on the newly established HER2-CasMab.